- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03439371
Micro-transplantation in Elderly Patients With Acute Myeloid Leukemia (MTSA)
May 4, 2023 updated by: Centre Hospitalier Universitaire de Saint Etienne
A Phase II, Multicenter, Open Label Study Evaluating the Efficacy and the Tolerance of Micro-transplantation in Elderly Patients With Acute Myeloid Leukemia (MTSA)
This study aims at evaluating the safety and the tolerance of the micro-transplantation in elderly patients with acute myeloid leukemia who are ineligible to conventional allogeneic transplantation.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Acute Myeloid Leukemia (AML) is an aggressive hematological malignancy with a median age at diagnosis of 65 years.
Outcomes of AML in elderly population remain unsatisfactory with low rates of complete remission, poor disease-free and overall survival.
Therapeutic management of older patients with AML deals with patient-related features (i.e.
comorbid conditions and performance status) as well as disease-related prognostic factors (i.e.
cytogenetics and molecular genetics).
Even if allogeneic hematopoietic-cell transplantation provides the strongest antineoplasic effect, this treatment option remains limited for older patients owing to toxicities, the development of significant graft-versus-host disease (GVHD) and logistics of donor availability.
More recently, micro-transplantation has emerged as an alternative strategy based on the infusion of mobilized HLA-mismatched related donor cells after induction chemotherapy, thus exerting a graft-versus-leukemia effect without substantial donor engraftment and GVHD.
Therefore, there is much of interest in investigating the efficacy and the safety of this method for older patients with AML who are not candidates for allogeneic stem cell transplantation.
Study Type
Interventional
Enrollment (Anticipated)
21
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jérôme Cornillon, MD
- Phone Number: +33 04 77 91 67 26
- Email: jerome.cornillon@chu-st-etienne.fr
Study Contact Backup
- Name: Elisabeth Daguenet, PhD
- Phone Number: +33 04 77 91 70 89
- Email: elisabeth.daguenet@chu-st-etienne.fr
Study Locations
-
-
-
Clermont-Ferrand, France, 63000
- Recruiting
- Chu Estaing
-
Contact:
- Jacques-Olivier Bay, MD
-
Principal Investigator:
- Jacques-Olivier Bay, MD
-
Sub-Investigator:
- Romain Guieze, MD
-
Sub-Investigator:
- Eric Hermet, MD
-
Sub-Investigator:
- Richard Lemal, MD
-
Sub-Investigator:
- Aurélie Ravinet, MD
-
Sub-Investigator:
- Olivier Tournilhac, MD
-
Sub-Investigator:
- Amandine Fayard, MD
-
Sub-Investigator:
- Victoria CACHEUX, MD
-
Grenoble, France
- Recruiting
- Centre Hospitalier Universitaire de Grenoble
-
Contact:
- Claude-Eric Bulabois, MD
-
Principal Investigator:
- Claude-Eric Bulabois
-
Sub-Investigator:
- Martin Carré
-
Sub-Investigator:
- Anne Thiébaut
-
Lille, France
- Not yet recruiting
- CHRU de Lille
-
Contact:
- Micha Srour
-
Principal Investigator:
- Micha Srour, MD
-
Sub-Investigator:
- David Beauvais, MD
-
Sub-Investigator:
- Valérie Coiteux, MD
-
Sub-Investigator:
- Leonardo Magro, MD
-
Sub-Investigator:
- Ibrahim Yakoub-Agha, MD
-
Lyon, France
- Recruiting
- Centre Hospitalier Lyon Sud
-
Contact:
- Hélène Labussière-Wallet, MD
-
Sub-Investigator:
- Marie Balsat, MD
-
Sub-Investigator:
- Fiorenza Barraco, MD
-
Sub-Investigator:
- Sophie Ducastelle-Lepretre, MD
-
Sub-Investigator:
- Gaëlle Fossard, MD
-
Sub-Investigator:
- Maël Heiblig, MD
-
Sub-Investigator:
- Marie-Virginie Larcher, MD
-
Sub-Investigator:
- Sandrine Loron, MD
-
Nancy, France
- Not yet recruiting
- Centre Hospitalier Universitaire de Nancy
-
Contact:
- Arnaud Campidelli, MD
-
Principal Investigator:
- Arnaud Campidelli
-
Sub-Investigator:
- Maud D'Aveni
-
Sub-Investigator:
- Marie Detrait
-
Sub-Investigator:
- Marie-Thérèse Rubio
-
Paris, France
- Not yet recruiting
- Hôpital de la Pitié-Salpétrière
-
Contact:
- Stéphanie Nguyen, MD
-
Principal Investigator:
- Stéphanie Nguyen, MD
-
Sub-Investigator:
- Laetitia Souchet, MD
-
Sub-Investigator:
- Madalina Uzunov, MD
-
Saint-Étienne, France, 42055
- Recruiting
- CHU DE SAINT-ETIENNE
-
Contact:
- Jérôme Cornillon, MD
-
Principal Investigator:
- Jérôme CORNILLON, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
60 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patient affiliated to a social security regimen or beneficiary of the same
- Signed written informed consent form
- Patient, ≥ 60 years-old - < 75 years-old, with established diagnosis of de novo or secondary AML with intermediate-risk or adverse-risk cytogenetic profile, or with established myelodysplasic syndromes (RAEB), in pathologically confirmed complete remission following anti-leukemic induction therapy (<5% blasts)
- Contra-indication to conditioning regimen in conventional allogeneic transplantation
Exclusion Criteria:
- Patient with established diagnosis of acute myeloid leukemia with standard-risk cytogenetic profile
- Promyelocytic leukemia t(15;17)
- CBF-AML t(8;21) or inv(16)
- Normal karyotype with a favorable molecular profile: NPM1+ and FLT3-; NPM1+, FLT3- and double mutation CEBPα or chronic myeloid leukemia in blastic phase
- Patient under guardianship or deprived of his liberty or any condition that may affect the patient's ability to understand and sign the informed consent
- Refusing participation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HLA-mismatched micro-transplantation
|
HLA-mismatched micro-transplantation after induction chemotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of overall survival
Time Frame: 2 years
|
Rate of overall survival will be reported.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hematopoietic recovery
Time Frame: 3 months
|
Number of platelets will be reported.
|
3 months
|
Hematopoietic recovery
Time Frame: 3 months
|
Number of neutrophils will be reported.
|
3 months
|
Hematopoietic recovery
Time Frame: 3 months
|
Percentage of leukaemic blasts will be reported.
|
3 months
|
Rate of complete remission
Time Frame: 2 years
|
Rate of complete remission :
|
2 years
|
GVHD (graft versus host disease)
Time Frame: 2 years
|
Presence of graft versus host disease will be reported.
|
2 years
|
Median overall survival
Time Frame: 2 years
|
Median overall survival will be calculated.
|
2 years
|
Median progression-free survival
Time Frame: 2 years
|
Median progression-free survival will be calculated.
|
2 years
|
Microchimerism
Time Frame: 3 months
|
Presence of microchimerism will be reported.
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Jérôme Cornillon, MD, CHU DE SAINT-ETIENNE
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 8, 2019
Primary Completion (Anticipated)
December 31, 2023
Study Completion (Anticipated)
December 31, 2025
Study Registration Dates
First Submitted
February 5, 2018
First Submitted That Met QC Criteria
February 13, 2018
First Posted (Actual)
February 20, 2018
Study Record Updates
Last Update Posted (Estimate)
May 5, 2023
Last Update Submitted That Met QC Criteria
May 4, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017-1201
- 2017-A03572-51 (Other Identifier: ANSM)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Massachusetts General HospitalCelgene CorporationTerminatedAcute Myelogenous Leukemia | Acute Myeloid Leukemia (AML) | Acute Myelocytic Leukemia | Acute Granulocytic Leukemia | Acute Non-Lymphocytic LeukemiaUnited States
-
Peking University People's HospitalBeijing JD Biotech Co. LTD.RecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryChina
Clinical Trials on HLA-mismatched micro-transplantation after induction chemotherapy
-
H. Lee Moffitt Cancer Center and Research InstituteActive, not recruitingMyelodysplastic Syndromes | Secondary Acute Myeloid LeukemiaUnited States
-
Nanfang Hospital, Southern Medical UniversityZhujiang HospitalCompletedAcute Myeloid Leukemia | Risk Stratification
-
Sun Yat-sen UniversityTerminatedTreatment RefusalChina
-
St. Jude Children's Research HospitalCompletedAcute Myeloid Leukemia | Leukemia | Hodgkin's Lymphoma | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Non-Hodgkin Lymphoma | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Paroxysmal Nocturnal HemoglobinuriaUnited States
-
St. Jude Children's Research HospitalAssisi FoundationCompletedAcute Myeloid Leukemia | Chronic Myeloid Leukemia | Acute Lymphocytic Leukemia | Histiocytosis | MyelodysplasiaUnited States
-
Affiliated Hospital to Academy of Military Medical...UnknownHematopoietic Stem Cell Transplantation | Graft-versus-host DiseaseChina
-
Hospital Israelita Albert EinsteinCompletedAcute Myeloid Leukemia | Myelodysplastic Syndromes | Myeloproliferative Neoplasms | Myeloproliferative/Myelodysplastic NeoplasmBrazil
-
St. Jude Children's Research HospitalCompletedLymphoma, Non-Hodgkin | Hodgkin Disease | Chronic Myeloid Leukemia | Acute Myeloid Leukemia (AML) | Acute Lymphoblastic Leukemia (ALL) | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Myelodysplastic Syndrome (MDS) | Secondary AML | Juvenile Myelomonocytic Leukemia (JMML) | Secondary MDSUnited States
-
The Affiliated Hospital of the Chinese Academy...Completed
-
WiSP Wissenschaftlicher Service Pharma GmbHCompleted